Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allied Healthcare Group Ltd Granted CE Mark For Lead Regenerative Product Cardioce


Sunday, 25 Aug 2013 06:00pm EDT 

Allied Healthcare Group Ltd announced that CardioCel has received CE mark approval, allowing the Company to launch and market the product in Europe. The Company will now look to take advantage of this CE mark to launch and start selling the product throughout Europe. The CE mark for CardioCel allows for the repair and reconstruction of heart defects including treating congenital heart disease and repairing heart valves in both children and adults. In addition to commercial and scientific validation, the approval of CardioCel technology in Europe offers a platform to launch additional cardiovascular products, as well as regenerative tissue products for the repair and reconstruction of other defects and diseases. Allied Healthcare Group is expecting sales of CardioCel in Europe to begin in the fourth quarter this calendar year. 

Company Quote

0.115
0.0050 +4.55%
24 Dec 2014